Abnormal Calcium Handling by Platelets in Thrombotic Disorders
thrombosis. The platelet activation has been shown to be an important step in the initiation of the arterial thrombosis 1 ' 4 such as stroke, myocardial infarction, and peripheral vascular diseases. The progress of the venous thrombosis can also be accelerated by activation of platelets at the site of thrombosis. 5 " 7 The mechanism of platelet activation is under active investigation. Many intracellular pathways for platelet activation have been demonstrated. Major pathways include the increase of cytoplasmic Ca 2+ concentration, 8 the formation of thromboxane A 2 , 9 and the breakdown of phosphatidylinositols. 10 " 12 Although the interactions between these pathways are very complicated," Ca 2+ influx or mobilization has been shown to be intimately involved in all these pathways. 13 " 16 Also, it has been shown that an increase of cytoplasmic Ca 2+ concentration to a critical level is a sufficient stimulus for the shape change," release reaction, 18 and aggregation 19 -20 of platelets. Numerous platelet function tests have been developed to detect platelet hyperactivation in various disorders. 21 " 23 These methods include platelet adherence on glass beads 2425 or collagen-coated surfaces, 26 platelet aggregation in the aggregometer, 2728 detection of circulating platelet aggregates, 29 assays for the release of platelet factor 4, 30 /3-thrombogobulin, 31 and assay for platelet procoagulant activity. 5 None of these methods provides direct information on the intracellular mechanisms of platelet hyperactivation.
To date, little work has been done on the Ca 2+ homeostasis of platelets from patients with various diseases. Erne et al 32 recently reported that elevated cytoplasmic Ca 2+ concentrations were detected in platelets from hypertensive patients. The present communication focuses on Ca 2+ handling* abnormalities in platelets from patients with arterial and venous thrombosis. In a previous paper, 33 it was shown that chlorotetracycline (CTC) fluorescence is a measure of Ca 2+ accu-*We prefer the term "calcium handling" to calcium homeostasis because calcium handling processes occur both in homeostasis and in Ca 2 + -triggered aggregation and secretion. The focus of the present study is calcium handling by the plasma membrane and by the dense tubular membranes and resulting cytoplasmic and dense tubular free Ca 2+ concentrations. 
Materials and Methods
Apyrase, antimycin A, oligomycin, ethylene glycol-bis-(amino-ethyl ether)-N,N'-tetraacetic acid (EGTA), collagen (type I), digitonin, and (d,l) verapamil were purchased from Sigma Chemical Co., St. Louis, Mo. Other reagents were obtained as follows: chlorotetracycline, ICN Pharmaceutical, Cleveland, Ohio; quin2/AM .Lancaster Synthesis Ltd., England; and trifluoperazine, Smith Kline & French, Philadelphia, Penn. The remaining reagents for Tyrode's solution were purchased from Mallinkrodt.
Blood Collection
Blood was drawn by peripheral venipuncture from normal donors and patients. After the first 2 ml of blood was discarded, blood was collected into plastic syringes or silicone coated vacuum containers containing solution of anticoagulant citrate dextrose (ACD). The volume ratio of blood to ACD was 9 to 1. The final concentration of citrate in the whole blood is 11 mM. To ensure that the blood collection technique was well controlled, paired studies on the influence of blood collection technique on the calcium-CTC ratio were performed. One portion of the blood was drawn into the plastic syringe from one arm of the donor and another portion of the blood was drawn into a vacutainer from the other arm of the same donor. No significant difference in the calcium-CTC ratio was found by collecting with the plastic syringe or vacutainer as long as the first 2 ml of blood was discarded.
Platelet Preparations
Platelet rich plasma (PRP) was obtained by centrifuging the whole blood at 150g for 10 minutes at room temperature (25° C). Then 4 mM EGTA was added to PRP, and the platelets were separated from plasma by a centrifugation at 600g for 7 minutes. The platelets were washed and suspended in Ca 2+ -Mg 2+ free Tyrode's solution according to the method of Mustard et al. 35 The final mM concentration of the solution was NaCl 138, KC1 3, glucose 10, NaHCO 3 2, NaH 2 PO 4 0.4, HEPES 2.5. The pH was adjusted to 7.35 and checked on an hourly basis. All platelet preparations were used within 4 hours of venipuncture.
Fluorescence Measurements
Fluorescence was measured in a Perkin Elmer (model MPF-3L) fluorometer as previously described. 33 CTC fluorescence was measured at 390 nm excitation and 530 nm emission. The light scattering artifacts were reduced by employing a single polarizer in the excitation beam 36 and a 510-nm cut-off filter in the emission beam. The quin2 fluorescence was recorded at 340 nm excitation and 492 nm emission. The polarizer and 460 nm cut-off filter were used. The platelet concentration for fluorescence measurements was adjusted to 1.6 x 10 7 platelets/ml. Trivial fluorescence artifacts such as "inner filter effect" 37 or light scattering artifacts were not observed.
Measurements ofCa 2+ Accumulation in Intracellular Organelles of Platelets by "Calcium-CTC Ratio"
The mechanism by which CTC measures Ca 2+ accumulation in the dense tubule and mitochondria of the platelet was described in detail in the previous paper. 33 Dense tubular Ca 2+ accumulation by the organelles was measured by the following procedure: The washed platelet suspension (1.6 x 10 7 platelet/ml in the Ca 2+ -Mg 2+ free Tyrode's solution) was incubated with CTC (10 fiM) in the fluorometer at 37° C for 15 minutes in a Ca 2+ -free medium (the free Ca 2+ concentration in the extracellular medium, [Ca 2+ ] 0 , approximately 1 /xM). Then calcium was added to the platelet suspension to a final concentration of 2 mM. As shown in the Figure 1 , the addition of Ca 2+ gives rise to an instantaneous increase of fluorescence (fast phase) followed by a slow increase of fluorescence with t,^ = 5-8 min (slow phase).
Previous analysis 33 has shown that the binding of the Ca-CTC complex on the outside surface of plasma membrane makes the major contribution to the fast phase. Formation of the Ca-CTC complex in the external medium makes a minor contribution. The analysis showed that the slow phase represents the Ca 2+ influx and active accumulation into the Ca 2+ sequestering organelles, and that its amplitude is proportional to the free Ca 2+ concentration in the organelles. Previous analysis shows that storage granules do not make a contribution and that the Km for active Ca 2+ uptake by the mitochondria is much higher than that of the dense tubules. 33 Thus, under "resting" conditions the slow phase amplitude of the CTC response is dominated by the dense tubular contribution. It is proportional to the free Ca 2+ concentration in the dense tubular lumen
The "calcium-CTC ratio" is calculated as the ratio of the amplitude of the slow phase to the amplitude of the fast phase taken 15 minutes after Ca face area of platelets. The choice of 15 minutes as an end point was made to limit the time requirements of the assay. In normal platelets, the slow phase amplitude is 80% of maximal at 15 minutes. In the abnormal samples, the uptake required longer than 15 minutes to reach 80% completion. Truncation at 15 minutes also had the effect of limiting both the degree of slow alkalinization of the medium (approximately 0.2 pH units) and the possible contribution of mitochondrial uptake. As noted above, the latter is a slower process with a higher Km for cytoplasmic Ca 2+ than the dense tubules.
Measurement of Cytoplasmic Free Ca 2+ Concentration by Quin2IAM Experiments
Quin2/AM loading of platelets followed the procedure of Rink et al 20 with some modification. PRP was incubated with quin2/AM (60 £iM) for 45 minutes, and then the platelets were washed until the internally trapped quin2 represented 99% of the cell-associated indicator. The cytoplasmic free Ca 2+ concentrations ([Ca   2+ ] c>rt ) were estimated using the equation:
as described by Tsien et al. 34 The Kd of the reaction was taken as 115 nM. The variable F is the observed fluorescence at the to-beTineasured cytoplasmic Ca 2+ concentration. The values of F mai and F min were determined in situ by Ca 2+ saturation and Ca 2+ depletion (excess EGTA) after digitonin-permeabilization of the platelets.
Measurement of Platelet Aggregation
The platelet aggregation was measured by monitoring the absorbance change (log 1/T) of diluted PRP in a Beckman spectrophotometer (Model DB-G), the instrument available at the time of these studies. Absorbance was measured at 600 nm wavelength with stirring (600 rpm) at room temperature (25° C). The PRP was diluted with Ca 2+ -free physiological saline (Tyrode's solution). The final pH in diluted PRP was adjusted to equal the undiluted PRP. Platelet counts under study conditions were estimated at 4 x 10 7 platelets/ml and were identical for patients and normal controls. 38 less influenced by positive feedback interactions between platelets (e.g., exocytotic ADP release). 2) Dilution of plasma factors would diminish their contribution to the above. 3) The kinetics are more easily studied, and the differences between normal and patient samples are accentuated. The choice of temperature (25° C) also resulted in slower rates. Initial rates of aggregation were measured as the maximal rate of absorbance change that was observed after a lag. The lag time was measured as time between collagen addition and commencement of the aggregation response, determined by extrapolation of the initial rate in baseline. 39 Repeated measurements with several controls on different occasions showed the results deriving from this protocol to be highly reproducible. The instrument is not sensitive to the shape change, probably because it has a narrow entrance and exit slit and excludes forward-scattered light. The lag time is the time for platelet activation and formation of small aggregates; the initial rate of the absorption change measures the rate of formation of large aggregates. 4041 
Patient Populations Studied
Platelet Ca 2+ handling as measured with calcium-CTC ratios was studied in the following groups of controls and patients:
GROUP I -NORMAL HEALTHY CONTROL: A total of 54 normal, healthy volunteers were selected as a control group. No medication had been taken by normal donors for 2 weeks before blood was drawn. The ages of normal donors ranged from 20-65 years with 80% of total normal donors being male. The mean age of normal controls was 35.
GROUP II -PATIENT CONTROLS: The choice of patient controls was based on a random selection of patients with diseases that did not involve thrombosis or any known platelet-related illness. This group included patients with skin diseases (5), localized infection or tumors (4), degenerative joint disease (2), atrial septal defect (1), BPH (1), obesity (1), iron deficiency (1), local trauma (1), and patients admitted for elective surgery (5). There were 11 women and 10 men with a mean age of 53.
GROUP III -ARTERIAL THROMBOSIS: Fourteen patients with cardiovascular accident (CVA) (9 men, 5 women; mean age 59) were studied. Diagnosis of CVA was confirmed either by computed axial tomography (CAT) scan or angiogram. Seven were suffering from recurrent transient ischemic attacks. Blood samples were drawn when their disease conditions were stable or when acute episodes subsided. Two were on aspirin and 1 was on dipyridamole at the time of study. All 3 had high calcium-CTC ratio. The remainder of patients were not on any medication known to affect platelet functions.
Additionally, 6 patients (5 men, 1 woman; mean age 44) with occlusive peripheral vascular disorders (PVD) with intermittent claudication were chosen for study. Arterial insufficiency was confirmed by either arteriogram or the Doppler method. None were on medication known to inhibit platelet function. All were in stable phases of their diseases at the time of study.
GROUP IV -VENOUS THROMBOSIS: This group included 16 patients with deep vein thrombosis (13 men, 3 women; mean age 48). Blood samples were drawn a few days after admission to the hospital for suspected deep vein thrombosis (DVT) in 14 patients and at clinics in 2 patients. Diagnosis of DVT was made on the basis of clinical signs and symptoms and was confirmed by venogram or CAT scan 42 in all patients except 2 who had histories of recurrent multiple venous thrombosis for years and presented with typical physical findings. Eleven patients were on heparin, 3 on coumadin, and 2 were on no medication at the time of study.
Results
A previous study showed that CTC fluorescence can be used as a linear measure of the free Ca 2+ concentration in the dense tubular lumen. 33 The Figure 1 compares the CTC response to Ca 2+ addition (to 2 mM) for platelets from a normal donor (Curve B) and for platelets from a patient with arterial thrombosis (Curve A). There is little difference between the fast phase amplitudes of the normal control and the thrombotic patient. In the patient sample, the slow fluorescence response to Ca 2+ addition shows a larger amplitude, indicating a higher Ca 2+ accumulation in the intracellular Ca 2+ sequestering pools. As will be shown below, this is a typical response of platelets from patients with arterial and venous thrombosis. The site of Ca 2+ uptake is identified as dense tubule by previously applied criteria. 33 Figure 1 shows that the slow phase can be completely inhibited by pretreating platelets with trifluoperazine plus antimycin A and oligomycin (Curve C). Without trifluoperazine, mitochondrial inhibitors antimycin A plus oligomycin inhibit the amplitude of slow phase only slightly (10% inhibition, data not shown). Since trifluoperazine has been shown to inhibit dense tubular Ca 2+ uptake when used at this concentration, 33 1 4344 the data identified the dense tubule as the major site for intracellular Ca 2+ accumulation in the resting state.
The calcium-CTC ratio (ratio of slow phase to fast amplitude) was taken as the index of Ca 2+ handling and compared the values of normal donors with those of various thrombotic diseases. The slow phase was normalized to the fast phase (calcium-CTC ratio) in order to give internal standardization of the fluorescence signal, which is otherwise a function of lamp intensity, slit widths, and other instrument determinants. The values of the fast-phase amplitude vary less than 20% between particular normal samples on a particular day.
Importantly, there was no significant difference between the fast-phase amplitude of patient samples and normal samples. This was revealed by the paired / test. Each pair was composed of a patient and a normal sample analyzed at the same day for an accurate comparison. The ratio of the fast phases between the patient and normal samples was calculated. For 20 pairs, the mean ± SD of the ratio of the fast phases was equal to 0.99 ± 0.21, indicating no significant difference in the fast phase between normal controls and thrombotic patients. This led us to conclude that the difference in the CTC ratio (slow phase/fast phase) is mainly due to the difference of the slow phase. Experiments (Table  1) with normal platelets show the calcium-CTC ratio is independent of the platelet concentration in the cuvette (ranging from 8 X 10 6 to 6.4 x 10 7 platelets/ml). Also, variations in platelet size distribution in the samples (Coulter counter model S plus 4) were small and could not be responsible for the difference in the calcium-CTC ratio. Size analysis showed that there is no significant difference of the mean platelet volumes between controls and patients (normal controls, 8.8 ± 1.0 jum The mean ± SD of each group is shown.
•The t test shows that difference between the normal control and the patient control is not significant (p > 0.1). tThe difference between the normal control and the group of disease is highly significant (p < 0.005) as calculated by the t test. Table 2 compares the calcium-CTC ratio for platelets from normal controls, patient controls, and thrombotic disorders. The calcium-CTC ratio of normal control is 0.40 ± 0.10 (mean ± SD, n = 54). As a control, this parameter was analyzed as a function of age in the normal population. Analysis showed that there is no significant difference of calcium-CTC ratio between age groups below 30 (n = 32), 30-40 (n = 13), 40-50 (n = 6), and above 50 (n = 3) in normal controls (data not shown). The calcium-CTC ratio of normal males (0.39 ±0.10, n = 42) is not significantly different form normal females (0.42 ± 0.12, n = 12). The calcium-CTC ratios of platelets from thrombotic diseases show higher mean values and larger variations. The t test analysis of the data of Table 2 shows highly significant (p< 0.005) differences between normal control vs. arterial thrombosis, venous thrombosis. The mean values of the calcium-CTC ratio from arterial and venous thrombosis are 1.7-2.1-fold higher than those of the control group. Thus, the net Ca 2+ accumulation in the dense tubules of platelets from these patients is approximately twofold higher than that of normal control. The data of patient controls shows that abnormal Ca 2+ handling reflected by the calcium-CTC ratio is not a general phenomenon for every type of disorder. 33 and where K,,, is an apparent K m for the maximal uptake at steady-state. The equation predicts that the uptake has a second power dependence identifies the uptake as dense tubular. The small contribution of the mitochondria uptake in the resting state will be described in a future study.) The fact that the results can be fitted with a single curve tends to rule out the possibility that the Ca 2+ affinities of the dense tubular Ca 2+ pumps are different between normal controls and thrombotic patients. In that case, two separate curves would have been observed with the abnormal one shifted to the left.
Abnormal Ca 2 * Handling of Platelets From Patients With Arterial and Venous Thrombosis

Relation Between
Effect of Verapamil on Co2* Accumulation of Platelets From Patients With Arterial and Venous Thrombosis
The observation of higher Ca 2+ accumulation and higher cytoplasmic Ca 2+ concentration in platelets from these patients (Table 2, Figure 2 ) agrees with our proposal that the higher Ca 2+ accumulation is due to the higher Ca 2+ influx through the plasma membrane. 45 " 47 To test this possibility, the platelets were pretreated with the Ca 2+ channel blocker verapamil 48 ' 49 to block the Ca 2+ influx through the activated Ca 2+ channel. Figure 3 shows the different effects of verapamil on the calcium-CTC ratio of platelets from normal donors and patients with thrombosis. The platelet suspension was incubated with verapamil for 15 minutes prior to the addition of Ca 2+ . With increasing concentration of verapamil, the calcium-CTC ratio of platelets from patients with thrombosis was lowered to the range of normal controls. The concentration for 50% inhibition for this effect of verapamil on the calcium-CTC ratio is about 11/AM. The figure also shows that the calcium-CTC ratio of platelets from normal donors is only slightly inhibited by the verapamil (8-10% inhibition) . No further inhibition of calcium-CTC ratio was observed in platelets from normal controls and patients for verapamil concentrations from 40-100/XM. The difference in verapamil effects on platelets from normal donors and thrombotic patients indicate that a higher Ca 2+ influx through the activated Ca 2+ channels is the major cause of the higher Ca 2+ accumulation in platelets from patients with thrombosis. The finding that the calcium-CTC ratios for patients and normals are identical at 40 and 60 ^iM verapamil indicates that the verapamil insensitive Ca 2+ leak (basal Ca 2+ leak) is the same for these two groups.
Higher Ca
* Accumulation Is Associated With Platelet Hyperaggregation
Since Ca 2+ is a primary trigger for platelet aggregation, is is possible that the platelet hyperaggregation associated with many vascular occlusive diseases 21 " 23 is the result of abnormal Ca 2+ handling. Present results, shown in Figure 4 , strongly indicate this possibility. The figure shows the linear correlation between calcium-CTC ratio and the rate of collagen, or induced platelet aggregation. The reaction was initiated by adding collagen (12.5 /ig/ml) to the fivefold diluted PRP (platelet count approximately 4 x 10 7 /ml: [Ca 2+ ] 0 approximately 135 fiM; T = 25°C). The results show a good correlation between calcium-CTC ratios and initial rate of aggregation (r = 0.89, p<0.001) ( Figure  4a ) and lag time of aggregation (r=-0.80, p<0.001) (Figure 4b ). The t test shows that platelets from thrombotic patients have a higher rate of aggregation and shorter lag time than those of normal controls. The data for the rate of aggregation (Abs/min) are as follows: thrombotic patients, 0.16 ± 0.039, n = 24 vs. normal controls, 0.087 ± 0.026, n = 2l (p<0.0l). The data for the lag time (seconds) are as follows: thrombotic patients, 84 ± 20, n = 24 vs. normal controls 128 ± 20, n = 21 (/?<0.05).
Discussion
This study shows that the calcium-CTC ratio method is a convenient and useful diagnostic of the Ca 2+ handling abnormalities in human platelets. CTC and quin2 results demonstrate an excellent mathematical correlation of the elevation of dense tubularly sequestered Ca 2+ with elevation of plasmic levels of Ca 2+ in platelets from patients with thrombosis. We believe this is more than a mere mathematical correlation because Figure 2 makes use of an experimentally-determined end point (Ratio mai ) and power dependence on [Ca 2+ ] cyt for dense tubular uptake and because the fitted equation delivered an apparent Km close to that obtained in independent experiments designed to determine that quantity. This points to elevated [Ca 2+ ] t as the primary cause of the elevated dense tubular Ca Figure 2 ). The results show that dense tubular Ca 2+ levels respond directly to cytoplasmic levels in the resting state, both for the normal controls and for arterial and venous thrombosis patients. The correlation of Figure 4 indicates that the calcium-CTC ratio is an indicator of platelet hyperactivation as measured by tests of aggregation.
The contribution of the intracellular Mg 2+ and storage granule associated Ca 2+ to CTC fluorescence was shown to be negligible. 33 The wavelengths of excitation (390 nm) and emission (530 nm) of CTC fluorescence are far away from the interference of the NADH fluorescence (emission 450 nm). The use of the ratio instead of raw amplitude provides the consistent basis for the comparison of different individuals and variations of platelet concentration. All of these data strongly suggest this method may be useful as a clinical test for abnormalities in Ca 2+ handling of platelets. The use of calcium-CTC ratio as a clinical predictor of the risk of thromboembolism is also an interesting application that will be pursued in the future. PLATELETS. Figure 5 is the minimal mechanism necessary to explain our results on Ca 2+ handling in normal and abnormal platelets, derived from our experimental results and previously reported data.
3345 " 47 Our data suggest that the [Ca 2+ ] cyl of the normal platelets in the resting state is maintained at approximately 0.11 /AM 20 ( Figure 2 ) by the balance between the Ca 2+ influx, the Ca 2+ extrusion, and (transiently) intracellular Ca 2+ uptake. Ca 2+ influx was shown to be mainly through the verapamil-insensitive Ca + influx 43 ( Figure 3 ). The latter is considered as a basal leak. The dense tubular system was identified as the major site for intracellular Ca 2+ uptake in the resting state 3343 ( Figure 1 (Figure 3 ). At the optimal effective dose of verapamil (40 (JM) , the basal leak is about the same in patients as in normal controls. Presently, it is not clear what mechanisms are responsible for the activated Ca 2+ channels that were observed in the resting state of washed platelets taken from the thrombosis patients. It is of interest that the difference between abnormal and normal platelets remains after isolation of the platelets from the plasma and persists for the time that isolated platelets are studied (up to 4 hours after blood was drawn). A number of mechanisms can be postulated. A likely mechanism involves chronic exposure to activating factors in the blood and periodic exposure to affected vascular endothelial surfaces. However, the possibility that the patients' platelets are intrinsically abnormal and become deranged during isolation cannot be rigorously excluded. The effect of a subcritical stimulus could not be amplified by the same autocatalytic mechanism that is responsible for normal activation and aggregation.
(It has recently been suggested to us that the differences that were observed between patient and control could represent easy activation of the former and that the true differences are exaggerated by the processes of blood drawing and preparation. To guard against spurious activation by puncture debris the first 2 ml of the blood were discarded. Also the platelets were rapidly isolated from the plasma before study of Ca 2+ levels. Spontaneous aggregation was not observed in any of our samples. Differences in the aggregation behavior of platelets isolated from patients and controls are, of course, well known.)
It is important to note that abnormal Ca 2+ handling, or specifically greater Ca 2+ permeability of the plasma membrane, is not completely specific for thrombosis. We have found that a number of disease conditions, including diabetes, hypertension, collagen diseases, idiopathic thrombocytopenia purpura, thrombotic thrombocytopenia purpura, hemolytic anemia, and myeloproliferative disorders are associated with higher calcium-CTC ratios. 465051 We believe that the ability of in vitro verapamil treatment to normalize Ca 2+ handling will be an important means of identifying the cause of derangements found in other diseases. handling measured by the calcium-CTC test in platelets isolated from these patients. 45 ' 4*i5° '51 Further study is necessary to determine whether this represents a direct or indirect effect of nifedipine on the platelet.
